Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been released, showing a 1.5% year-on-year increase in global revenues at constant exchange rates (CER), reaching JPY 4.3 trillion (USD 27.4 billion). This growth was achieved despite a significant impact from the loss of exclusivity on certain products. Although net profit fell by 15.0%, CEO Christophe Weber is optimistic about a return to sustainable revenue and profit growth starting in the fiscal year 2025, following a possible decline in 2024.
Over the 12-month period, Takeda’s gastrointestinal and inflammation unit saw an expansion of 4.7% to JPY 1.2 trillion, rare diseases increased by 4.1% to JPY 771 billion, plasma-derived therapies and immunology grew by 14.4% to JPY 819 billion, and oncology expanded by 2.5% to JPY 462 billion. In contrast, neuroscience declined by 7.8% to JPY 627 billion, and other therapeutic areas plummeted by 17.7% to JPY 369 billion.
The company’s top-selling drug was Entyvio (vedolizumab) for autoimmune diseases, contributing JPY 801 billion (USD 5.1 billion), followed by immunoglobulin sales at JPY 645 billion (USD 4.1 billion), and the central nervous system (CNS) stimulant Vyvanse/Elvanse (lisdexamfetamine dimesylate) at JPY 423 billion (USD 2.7 billion).
Geographically, the US market slipped by 2.2% to JPY 2.2 trillion, Europe and Canada rose by 4.5% to JPY 967 billion, Japan saw a significant collapse of 12.1% to JPY 451 billion, Asia ex-Japan climbed by 12.1% to JPY 261 billion, Latin America soared by 48.4% to JPY 198 billion, Russia/CIS fell by 6.5% to JPY 73 billion, and other markets increased by 32.6% to JPY 118 billion. While financial data for China was not disclosed, the report highlights China as a growth driver for acid-related diseases therapy Takecab/Vocinti (vonoprazan), antihemophilic Advate (octocog alfa), and albumin products such as Flexbumin (human albumin).- Flcube.com
